Atopic Dermatitis
Conditions
Interventions
Experimental Group:1.Baicalin Zhu Cooling Blood Combination (commissioned from Shanghai Baolong Pharmaceutical Co., Ltd., 30ml per bottle), 30ml each time, 2 times daily. The course of treatment was 2
The course of treatment was 2 weeks. 3.Bitter Sweet Cream is applied externally to the affected
Control Group:1.Baicalin Zhu Cooling Blood Combination (commissioned from Shanghai Baolong Pharmaceutical Co., Ltd., 30ml per bottle), 30ml each time, 2 times daily. The course of treatment was 2 week
The course of treatment was 2 weeks. 3.Desonide Cream is applied externally to the affected area
Sponsors
Shanghai Skin Disease Hospital, Institute of Dermatology, School of Medicine, Tongji University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.It meets the above diagnostic criteria for atopic dermatitis; 2.Age =18 years and =65 years, gender is not limited; 3.Investigator's global assessment (IGA) score of 2~3 or Eczema area and severity index (EASI) score of 1~21, diagnosed as mild to moderate AD patients; 4.Those who understood, agreed to participate in this study and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Other active skin diseases that may interfere with the assessment of the condition; 2. Patients have been systematically treated with investigational drugs, biologics and immunosuppressive agents within 1 month; 3. In a period of severe uncontrollable acute or chronic local or systemic infection; 4. Patients with severe systemic diseases; or patients whose clinical test indicators fall into one of the following categories: increased alanine aminotransferase or glutamine aminotransferase > 1.5 times the upper limit of normal; increased creatinine > 1.5 times the upper limit of normal; any of the major indicators of routine blood tests (white blood cell count, red blood cell count, haemoglobin volume, platelet count) is below the lower limit of normal; or other laboratory test abnormalities of the investigator Patients judged to be unsuitable for participation in this trial; 5. Patients with a history of malignancy and patients with primary or secondary immunodeficiency and hypersensitivity, or those with a family history of tumours; 6. Who have undergone major surgery within 8 weeks or will require such surgery during the study; 7. Women who are pregnant or breastfeeding; 8. Persons with a history of alcohol, drug or substance abuse; 9. Persons with a history or family history of severe mental illness; 10. Persons who, in the opinion of the investigator, are not suitable for participation in this study for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eczema area and severity index,EASI; | — |
Secondary
| Measure | Time frame |
|---|---|
| Dermatology quality of life index,DLQI;Visual analogue scale,VAS; | — |
Countries
China
Contacts
Public ContactBin Li
Shanghai Skin Disease Hospital, Institute of Dermatology, School of Medicine, Tongji University
Outcome results
None listed